CGRPtargeted

CGRPtargeted is a biopharmaceutical company focused on developing and commercializing therapeutics targeting calcitonin gene-related peptide (CGRP), a neuropeptide involved in various physiological processes, including pain modulation, inflammation, and vasodilation. The company's primary goal is to create innovative treatments for conditions characterized by excessive CGRP activity, such as migraine, cluster headache, and certain types of pain.

The company's lead product, erenumab, is a fully human, monoclonal antibody designed to selectively neutralize CGRP. Erenumab has demonstrated efficacy in clinical trials for the prevention of migraine and cluster headache, showing a significant reduction in the frequency and severity of headache episodes. The drug is currently in the regulatory review process for approval in various countries.

CGRPtargeted's approach involves a combination of in-house research and development, as well as strategic partnerships with academic institutions and other biopharmaceutical companies. The company's team of scientists and clinicians brings a wealth of expertise in neurology, immunology, and pharmacology to the development of CGRP-targeted therapies.

In addition to erenumab, CGRPtargeted is exploring other potential CGRP-targeting therapies, including small molecule inhibitors and other antibody-based approaches. The company's long-term vision is to expand its portfolio of CGRP-targeted products to address a broader range of neurological and inflammatory conditions.

CGRPtargeted is headquartered in Cambridge, Massachusetts, and operates as a private company. The company was founded in 2014 by a group of experienced biopharmaceutical professionals with a shared vision of developing innovative treatments for patients suffering from CGRP-related disorders.